Research Article |
Corresponding author: Ilango Kaliappan ( ilangok67@gmail.com ) Academic editor: Magdalena Kondeva-Burdina
© 2023 Bathula Sivakumar, Ilango Kaliappan.
This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Citation:
Sivakumar B, Kaliappan I (2023) Lead drug discovery from imidazolinone derivatives with Aurora kinase inhibitors. Pharmacia 70(4): 1529-1540. https://doi.org/10.3897/pharmacia.70.e114935
|
Cancer is the second leading cause of death worldwide, and breast cancer accounts for 6.27 million cases in the year 2022. In the present study, Quantitative Structural Activity Relationship (QSAR) studies were performed on a dataset of 39 molecules of Imidazolinone analogues using in random selection using QSARINS Software. The statistically validated (R2 = 0.8429 Q2loo = 0.7558) MLR model was used to predict the bioactivity of novel leads. Moreover, high-scoring compounds were exposed to molecular docking and molecular dynamic modeling study. Intended derivatives 1–23 exhibited the anticipated bioactivity using a QSAR model. Aforementioned molecules were tested for binding affinities with the target protein and the majority of them demonstrated excellent interactions with binding pocket residues. Molecular dynamics simulations using Desmond for 100 ns of top complexes 1, 7, 9, 13 and 19 showed critical structural data concerning Aurora kinase inhibition. There were stable hydrophobic and hydrophilic interfaces in the dynamic site of compounds with a leading chemical structure. The chemical interacts to the (PDB: 1MQ4) structure in a stable way, according to RMSD, RMSF, RoG, H-bond, and SASA analysis. Furthermore, the docking results have been confirmed by MM-PBSA and MM-GBSA. Based on our findings, we reported the inclusion of the necessary structural features of imidazolinone derivatives leads to the development of the potent candidates for further development.
Molecular descriptors, Molecular docking, Molecular dynamic study, QSAR
Breast cancer is a leading reason for mortality among women of all ages. It replaces lung cancer as that of the second-leading reason for death in women. In 2022, the world’s health organization (WHO 2022) predicted 6.27 million breast cancer-related deaths (
Aminothiazoles were found to be used as starting materials for synthesizing the sulpha drugs, fungicides, dyes and biocides, as a thyroid inhibitor used in the treatment of hyperthyroidism and also to have antibacterial activity. Recent studies have proven that aminothiazoles are also used in the treatment of prion diseases. Aurora kinases are threonine/serine kinases that play a crucial role in cell division. They aid in the dispensation of genetic material from growing cells to their daughter cells (
“QSARINS” enables the creation of numerous linear regression models using ordinary least squares, which are meticulously tested and validated using the chemometric technique. A series of amino thiazole derivatives with Aurora kinase inhibitory properties were selected from a 39-compound dataset (Suppl. material
The data collection, integration, curation, model creation, and model validation procedures are all included in the QSAR modelling study. Using an associated algorithm, a thorough analysis of the collected molecular descriptors yielded structure and bioactivity relationships. In our situation, atomic charges, Sanderson’s electronegativity, MoRSE descriptors, as well as 3D structural approximations constructed on electron diversion descriptors biased by volume, all played a significant part in predicting bioactivity (
Based on our study on the interactions between the hydrophobic and hydrophilic areas of the Brest cancer active site provided us with significant information for developing inhibitors. Table
Molecular descriptor principles and predicted pic50 value for the 23 designed derivatives.
Name | EstateVSA5 | PSA | MoRSEP3 | MATSp5 | RDFC24 | Pred.Pki |
---|---|---|---|---|---|---|
1 | 23.71 | 222.071 | -0.401 | -0.107 | 0.052 | 6.7417275 |
2 | 35.852 | 252.400 | -0.688 | -0.150 | -0.122 | 6.4286278 |
3 | 17.663 | 147.655 | -0.427 | -0.144 | 0.063 | 7.81143 |
4 | 23.719 | 259.48 | 0.008 | -0.144 | 0.176 | 7.6593774 |
5 | 35.852 | 125.67 | -0.400 | -0.132 | 0.026 | 7.3411652 |
6 | 44.005 | 275.522 | -0.154 | -0.142 | -0.015 | 6.349563 |
7 | 11.587 | 126.812 | -1.452 | -0.097 | 0.004 | 6.242778 |
8 | 30.829 | 268.487 | -0.067 | -0.146 | 0.048 | 5.740689 |
9 | 23.719 | 196.07 | -2.188 | -0.146 | 0.175 | 5.764796 |
10 | 47.975 | 233.577 | -1.053 | -0.135 | -0.139 | 5.505607 |
11 | 41.909 | 241.284 | -0.595 | -0.156 | -0.022 | 5.763515 |
12 | 11.587 | 259.962 | 0.070 | -0.15 | -0.024 | 5.849557 |
13 | 23.719 | 133.707 | -0.757 | -0.151 | -0.194 | 5.978507 |
14 | 11.577 | 167.313 | -1.129 | -0.107 | -0.006 | 5.846769 |
15 | 11.587 | 126.587 | -1.545 | -0.097 | 0.073 | 6.421773 |
16 | 47.975 | 154.355 | 0.382 | -0.097 | -0.069 | 6.283066 |
17 | 35.852 | 153.268 | -0.558 | -0.142 | -0.061 | 6.257293 |
18 | 29.786 | 145.244 | -1.45 | -0.122 | -0.013 | 6.720173 |
19 | 29.786 | 199.690 | -0.296 | -0.146 | 0.126 | 7.883326 |
20 | 11.587 | 128.361 | -0.751 | -0.136 | 0.102 | 5.816033 |
21 | 11.587 | 200.986 | -0.037 | -0.145 | -0.193 | 6.191462 |
22 | 29.776 | 151.861 | -1.570 | -0.139 | 0.017 | 6.373608 |
23 | 35.842 | 152.813 | -1.119 | -0.042 | 0.012 | 5.653782 |
The aforementioned conformations were imperilled to Insilco experiments in order to investigate the interactions between residues, H-bonds, and obligatory energy scores. The novel Aurora kinase pattern, PDB 3D structures: 1MQ4, was produced from the protein catalogue (www.rcsb.org) (
The ligand categorizer was constructed by accumulating polar hydrogens and employing Gasteiger charges. The Auto grid selection allows users to generate the energetic map using a distance-dependent dielectric continuous utility by identifying an active site and setting the element size to 60 * 60 * 60 points with 0.503 A0 spacing. The RMSD scores between the reference and predicted components were used to assess whether the docking simulation properly foretold a close-match docked pose or not (
The “Desmond V 5.9 software” was used to conduct simulations of molecular dynamics in order to investigate how the solvent system altered the molecular makeup of the proteinligand complex (Schrodinger 2019-3). The OPLS 4 force field was used for the docked complex’s MDS (ligand 1MQ4). For the sake of performing dynamic forces simulations, the complex’s site has been center filled in an orthorhombic cubic punnet, and TIP3P water molecules and buffers have been inserted at a distance of 10 A0 between the box edge and the protein atom (
Using the Nose-Hoover thermostat and Martyne-Tobias-Klein barostat practices, the temperature and compression balances were kept at 300 K and 1 atom, respectively. Every 50 ps, the simulation progress were methodically recorded. Succeeding the replication phase, which needs 100 ns of manufacturing, the NPT ensemble was initiated. The simulated interaction diagram was utilised to investigate the trajectories of the frames, which assisted in the discovery of variations (
Intended novel derivatives Founded on absolutely correlated with structurally and molecular descriptor information from the QSAR model pIC50 = 5.1811+0.0168*(EstateVSA5)+0.0043*(PSA)+0.7620*(MoRSEP3)+1.3270*(MATSp 5)+12.5951*(RDFC24).
ntr = 39 npred = R2 = 0.8429 R2adj = 0.7061 R2-R2adj = 0.0367 LOF = 0.0541 Kxx = 0.3885 DeltaK = 0.0714 RMSEtr = 0.1762 MAEtr = 0.1433 RSStr = 1.0241 CCCtr = 0.8525 s = 0.1912 F = 20.2223
Q2loo = 0.7558 R2-Q2loo = 0.1101 RMSEcv = 0.2105 MAEcv = 0.1702 PRESScv = 1.4625 CCCcv = 0.7954 Q2LMO = 0.6076 R2Yscr = 0.1289 Q2Yscr = -0.2219 RMSEAVYscr = 0.3239 RMSEext = 0.3697
MAEext = 0.3167 PRESSext = 0.8199 R2ext = 0.6726 Q2-F1 = -0.2977 Q2-F2 = -0.3627 Q2-F3 = -0.1322 CCCext = 0.6877 r2m aver = 0.2370 r2m delta = 0.4976
Using alkyl linkers on imidazolidinone and a 2-amino thiazole ring on the tail, the 2-amino thiazole imidazolidin-4-one core structure was investigated. ESI the dataset chemicals used to create the QSAR models are shown in Table
Applicability domain. Hat diagonal values versus standardized residuals.
The calculated novel derivatives with greatest pIC50 standards remained exposed to molecular docking studies for necessary empathy and H-bond interfaces estimate. Molecular docking was performed to investigate the potentiality of the chosen compounds, to engage the active cavity of Aurora Kinase in a way that would disrupt its tumorigenic activity. Many poses were observed and the poses with least score for each compound were considered. Interestingly, all the selected compounds except 2, 3, 10, 11, 12, 15 and 17 showed good interaction with the target in terms of glide score and energy; in particular than the reference compounds Tamoxifen and Arimidex. Results of the binding scores and the interactions with the amino acid residues are shown in Table
Amino acid interactions and docking scores ligand and significantly scored compounds.
Compound Code | Docking score (kcal/mol) | Glide energy (Kcal/mol) | H-bond interactions (distance in A0) |
---|---|---|---|
1 | -7.812 | -126.364 | LYS 143–1.96 |
LYS 162–2.27 | |||
ASN 261–2.48 | |||
ASP 274–2.01 | |||
2 | -3.551 | -136.422 | LYS 143–2.17 |
LYS 162–2.26 | |||
ALA 213–2.18 | |||
ASN 261–2.67 | |||
ASP 274–2.33 | |||
3 | -4.178 | -121.158 | ASP 256–1.93 |
ASN 261–1.92 | |||
4 | -7.505 | -128.895 | LYS 143–2.76 |
ALA 213–1.99 | |||
LYS 258–2.42 | |||
ASN 261–2.15 | |||
ASP 274–1.70 | |||
5 | -6.567 | -113.935 | LYS 143–2.05 |
LYS 258–3.34 | |||
6 | -6.282 | -129.258 | ASN 261–2.11 |
ASP 274–2.26 | |||
7 | -7.653 | -130.38 | LYS 143–1.83 |
LYS 162–2.04 | |||
ASN 261–2.51 | |||
ASP 274–1.88 | |||
8 | -6.677 | -131.410 | LYS 162–2.01 |
ALA 213–2.28 | |||
LYS 258–2.24 | |||
ASN 261–1.97 | |||
ASP 274–1.97 | |||
9 | -7.894 | -123.094 | LYS 162–1.69 |
ALA 213–2.09 | |||
LYS 258–2.50 | |||
ASN 261–2.11 | |||
ASP 274–2.03 | |||
10 | -3.030 | -130.443 | LYS 162–2.34 |
ASN 261–2.22 | |||
ASP 274–1.71 | |||
11 | -4.178 | -121.158 | LYS 143–2.07 |
LYS 162–2.23 | |||
12 | -3.449 | -122.071 | LYS 143–2.29 |
LYS 162–2.34 | |||
ASP 274–2.03 | |||
13 | -7.606 | -127.369 | LYS 143–1.69 |
ASN 261–2.33 | |||
ASP 274–1.80 | |||
14 | -6.680 | -132.345 | LYS 143–2.32 |
LYS 162–2.18 | |||
ASN 261–2.70 | |||
ASP 274–2.74 | |||
15 | -3.822 | -129.061 | LYS 143–2.32 |
LYS 162–2.19 | |||
ASN 261–2.55 | |||
ASP 274–1.94 | |||
16 | -6.534 | -119.101 | LYS 143–2.19 |
ASN 261–2.23 | |||
17 | -4.877 | -126.472 | LYS 143–2.58 |
LYS 162–1.94 | |||
18 | -6.044 | -126.472 | LYS 143–2.01 |
LYS 162–2.24 | |||
19 | -9.484 | -130.410 | LYS 162-1.98 |
GLU 211–2.19 | |||
ALA213–2.27 | |||
LYS 258–2.38 | |||
ASN 261–1.98 | |||
20 | -6.545 | -136.410 | LYS 143–1.91 |
LYS 162–1.91 | |||
ASN 261–2.24 | |||
ASP 274–1.87 | |||
21 | -6.523 | -124.212 | LYS 143–2.17 |
LYS 162–2.13 | |||
ASP 274–1.98 | |||
22 | -7.006 | -124.475 | LYS 143–2.00 |
LYS 162–2.02 | |||
ASN 261–2.24 | |||
ASP 274–1.90 | |||
23 | -7.520 | -124.332 | LYS 143–2.08 |
ASN 261–2.38 | |||
ASP 274–2.00 | |||
Tamoxifen | -5.003 | -52.219 | LYS 107–2.31 |
ASP 108–2.42 |
The superlative conformation of Derivatives 7- 1MQ4 multifaceted from Glide demonstrated obligatory empathy as -7.653KJ/mol-1. The sulfonyl and oxo groups of the compound showed interactions with the residues Lys143, Lys162, Asn261 and Asp274 through hydrogen bonding. Compared to the previous two compounds, this occupied different binding mode in the active pocket. The core thiazole imidazolidinone group shared four hydrogen bonds with the residues Lys143, Lys162, Asn261 and Asp274. In addition, a pi-pi interaction with the residue Trp277 was observed. Compound 1 shared five hydrogen bonds with the residues Lys162, Lys258, Asn261, Glu211 and Ala213. The thiazole group of the core component and the carbonyl sulphide of R1 shared hydrogen bonds with a single residue Lys 162. Interestingly, compound 19, 9 and 1, 7 showed similar binding modes respectively.
The best conformation of compound 13 - 1MQ4 complex from Glide displayed binding affinity as -7.520KJ/mol-1. Similar to compound 1, the thiazole group of the core component and the carbonyl sulphide of R1 shared hydrogen bonds with a single residue Lys 162. Apart from that the residues Asp274, Asn261 and Lys143 were found to have H-bonded interactions. Compound 23 also showed good interaction with a docking score of -7.520 KJ/mol. Four hydrogen bonds involving the residues Asn261, Asp274 and Lys143 were observed with Asp274 forming two hydrogen bonds.
The compound 4 with substituted Aromatic cinnamaldehyde interacted with ALA 213 and
Oxo amino group interact with LYS 143, ASN 261 and ASP274 by the hydrogen bonding. The compound 22 with amino thiazole group moiety interacted with LYS 162, ASP 274 and Oxo and amino group interacted LYS 143, ASN 261, via H-bond. Bromo benzene formed pi-pi interactions with Trp277. Also it is evident from the table and figures, that all the above mentioned compounds showed better binding affinity than the control drug Tamoxifen. In addition, compounds 14, 8, 5, 20, 16, 21, 6 and 18 also showed good binding affinity than tamoxifen as evident from (Table
Although molecular docking analyses have revealed the complex binding mechanisms (protein-inhibitor), molecular dynamics simulation can detect even the slightest disagreement. To find out as much as possible about the atomic specifics in the solvent system, the compounds 1, 7, 9, 13, and 19 with the best interactions and energy docked conformation were studied (Fig.
To study the stability of the bound complexes, the RMSD and RMSF calculations were performed. RMSD reflects the mobility of an atom during the MD simulation trajectory; with higher RMSD corresponding to higher mobility, whereas, lower RMSD corresponds to lower mobility. The RMSD plot indicates that the compounds 19, 9 and 7 stabilized shortly after commencing the simulation and found no major deviations throughout the simulation. Also a similar pattern of fluctuation was observed for both protein and ligand except for compound 13. For compound 19, the ligand RMSD varied from 0.91 to 2.48Å, whereas protein RMSD showed variation from 1.20Å to 2.19Å (Fig.
Gly173 is fluctuated to around 2.70 Å upon binding of Compound 19. Secondary structural analyses showed a loop to stand conversion around the 180th residue, induced by compound 19. In case of Compound1-AurK complex, fluctuations were observed in regions of Thr287 to Gly291. From the ligand RMSF graph, the carbonyl and the thiazole groups of compound 19 are exposed towards the surface, which is also evident from the 2D plot (from docking). The benzyl group of compound 1 showed higher fluctuations than the other regions, suggesting their exposure to the surface. The residues Thr287 and Thr288 have fluctuated a bit upon binding of compound 7. Notably, these fluctuations lie under the permissible range of 1–3Å. No major residual fluctuations were observed in Compound 9-AurK complex. However, of the residues GLY 142, LYS 143, PHE 144, Glu 170, LYS 171 and ALA 172 showed an increase in flexibility (>3Å) interaction with compound 13. Ligand RMSF (Fig.
Interactions histogram showed the interactions lasting over different simulation time and the connections that past additional than 30% of the simulation time are measured. It shows that most of the interactions of the docked pose were retained during simulation. Water-bridge, Hydrogen bonding following hydrophobic interactions at stable areas LEU 139, GLY 142, LYS 143, PHE 144, GLY 145, VAL 147, ALA 160, LYS 162, LYS 162, LEU 164, GLU 211, ALA 213, LYS 258, GLU 260, ASN 261, LEU 263, ASP 274 and TRP 277 were found in compound 19 during MDS (Fig.
Estimation of binding energy using the molecular mechanics-generalized born surface area (MMGBSA) system helps in identification of ligands that bind effectively. The bound complexes identified by molecular docking and MDS were further discovered by performing MMGBSA binding free energy calculations. The key contributors for binding namely Hbonding, lipophilic interactions, electrostatic interactions and Van der Waals energy were also estimated from the trajectories attained throughout MDS and depicted in (Table
The binding free energy particulars of the aurora kinase compounds 1, 7, 9, 13, 19 complexes.
Compound | Compound 1 | Compound 7 | Compound 9 | Compound 13 | Compound 19 |
---|---|---|---|---|---|
ΔGbind | -88.51 | -102.40 | -96.91 | -84.88 | -125.18 |
ΔGcoloumb | -32.31 | -30.07 | -43.86 | -33.56 | -36.72 |
ΔEHbond | -1.64 | -1.97 | -3.26 | -2.09 | -2.96 |
ΔElipo | -32.96 | -40.70 | -44.74 | -39.01 | -50.85 |
ΔEvdw | 7.27 | -68.75 | -71.36 | -73.87 | -81.21 |
Solv GB | 41.70 | 35.99 | 60.11 | 39.72 | 32.36 |
In this study employed a large-scale computational analysis of 39 compounds with imidazolinone backbones that exhibit inhibitory effects on aurora kinases. The primary objective was to identify the key structural characteristics and properties associated with the biological activity of these compounds against breast cancer, with the ultimate goal of enhancing their potential as successful leads in drug discovery. To achieve this objective, a hybrid strategy combining ligand-based and structure-based methods for drug development was utilized. Notably, the study relied on the properties of a quantitative structure-activity relationship (QSAR) model specifically developed for imidazolidin-4-one derivatives. This approach proved to be straightforward and highly effective in guiding the design of novel imidazolidin-4-one derivatives. The screening process incorporated various techniques, including QSAR, molecular docking, and molecular dynamics simulations. Molecular dynamics simulations were particularly valuable as they provided insights into the stability dynamics of selected compounds (1, 7, 9, 13 and 19) within the active site. Over the course of a 100 nanosecond trajectory, the MD simulations demonstrated a high degree of stability for all five examined complexes. Furthermore, the newly designed compounds were evaluated for their inhibitory effects on enzyme activity and other receptors. The results of these assessments, combined with the knowledge gained from the study, suggest that further modifications to the ring system could contribute to the development of lead candidates with significant potential as therapeutic agents for breast cancer treatment.
The authors declare that there are no competing financial interests.
No funding was received to assist with the preparation of this manuscript.
This work does not involve the use of humans or animals
All datasets collected and analyzed during this study are available in supplementary information.
Authors are grateful to The Management, SRM College of Pharmacy for their consistent support and encouragement.
Supplementary data
Data type: docx